Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated.
Bompas
Emmanuelle
E
Hôpital Edouard Herriot, 5 place d'Arsonval, 69437 Lyon Cedex 03, France.
Velay
Brigitte
B
Blay
Jean-Yves
JY
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001549:Benzamides; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008223:Lymphoma / Q000378:metabolism; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011239:Prednisolone / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage*; D012008:Recurrence; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; D011239:Prednisolone